Search

for
Search:

Community Join

5 / 942 results

community To go from photo 1 to photo 2 & 3 is kinda mind blowing to me. My barber today told me my hair looks thicker, it made my day.

in Progress Pictures 204 upvotes 2 years ago

A user shared progress pictures showing thicker hair after 8 months of using Fin/Min spray from HIMS. The conversation includes skepticism and humor from other users.

community 2 year update: 1.2mg Fin, 3mg Min

1100 upvotes 6 days ago

The user experienced diffuse hair loss and successfully regrew thicker hair using 1.2mg Finasteride and 3mg Minoxidil over two years. They noticed significant progress around the six-month mark and used Hims for their medication.

community Progress from September 2 - November 1

3 upvotes 10 months ago

A 23-year-old is experiencing hair thinning and has switched from topical minoxidil to a Hims finasteride/minoxidil combo with vitamins, feeling more confident and seeing progress. They seek opinions on their progress, noting minimal side effects and aiming for significant improvement by months 6-8.

community 3 months on 1.2mg fin and 3mg minoxidil 2.5mg biotin, oral pill

in Is this regrowth? 42 upvotes 10 months ago

A 25-year-old user shared their positive experience with hair regrowth after 3 months on 1.2mg finasteride, 3mg minoxidil, and 2.5mg biotin, with no side effects. Other users discussed their experiences with similar treatments, including Hims chewables, and shared optimism about the results.

community HYBRID TABLET PROGRESS - 1.1mg Fin / 3mg Min

147 upvotes 3 months ago

OP used HIMS hybrid tablets containing 1.1mg finasteride, 3mg minoxidil, and 2.5mg biotin, showing significant hair regrowth after initial shedding. OP experienced no side effects and plans to continue treatment.

View more "hims 2-in-1" in community →

Research

5 / 46 results

Continued Treatment With Baricitinib Results in Meaningful Scalp Responses Among Scalp Non-Responder Patients With Eyebrow/Eyelash Regrowth in the First Year

research Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year

November 2024 in “Journal of the European Academy of Dermatology and Venereology”

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

Long-Term Efficacy of Baricitinib in the Treatment of Alopecia Areata: Results at Week 104 from the BRAVE-AA1 and BRAVE-AA2 Studies

research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2

November 2023 in “Annales de dermatologie et de vénéréologie, FMC”

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

research Evaluation of Stigma Toward Individuals With Alopecia

38 citations , March 2021 in “JAMA Dermatology”

This cross-sectional survey study found that stigmatizing attitudes toward people with alopecia are present in various social and professional settings, with stigma levels varying by alopecia severity and perceptions of its medical nature.

research Local Corticosteroids for Alopecia Areata: A Narrative Review

8 citations , May 2025 in “Dermatology and Therapy”

This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.

View more "hims 2-in-1" in research →